EYPT vs. CTKB, LAB, QTRX, PACB, NAUT, HBIO, BNGO, AXDX, OLK, and TXG
Should you be buying EyePoint Pharmaceuticals stock or one of its competitors? The main competitors of EyePoint Pharmaceuticals include Cytek Biosciences (CTKB), Standard BioTools (LAB), Quanterix (QTRX), Pacific Biosciences of California (PACB), Nautilus Biotechnology (NAUT), Harvard Bioscience (HBIO), Bionano Genomics (BNGO), Accelerate Diagnostics (AXDX), Olink Holding AB (publ) (OLK), and 10x Genomics (TXG). These companies are all part of the "analytical instruments" industry.
Cytek Biosciences (NASDAQ:CTKB) and EyePoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, community ranking, profitability, earnings, risk, analyst recommendations and media sentiment.
Cytek Biosciences has a net margin of -6.29% compared to Cytek Biosciences' net margin of -153.84%. EyePoint Pharmaceuticals' return on equity of -1.40% beat Cytek Biosciences' return on equity.
In the previous week, EyePoint Pharmaceuticals had 24 more articles in the media than Cytek Biosciences. MarketBeat recorded 33 mentions for EyePoint Pharmaceuticals and 9 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.26 beat EyePoint Pharmaceuticals' score of -0.04 indicating that EyePoint Pharmaceuticals is being referred to more favorably in the news media.
Cytek Biosciences has higher revenue and earnings than EyePoint Pharmaceuticals. Cytek Biosciences is trading at a lower price-to-earnings ratio than EyePoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 99.4% of EyePoint Pharmaceuticals shares are owned by institutional investors. 15.9% of Cytek Biosciences shares are owned by company insiders. Comparatively, 13.1% of EyePoint Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
EyePoint Pharmaceuticals received 433 more outperform votes than Cytek Biosciences when rated by MarketBeat users. Likewise, 69.77% of users gave EyePoint Pharmaceuticals an outperform vote while only 41.46% of users gave Cytek Biosciences an outperform vote.
Cytek Biosciences has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, EyePoint Pharmaceuticals has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500.
Cytek Biosciences currently has a consensus price target of $9.00, suggesting a potential upside of 42.86%. EyePoint Pharmaceuticals has a consensus price target of $34.14, suggesting a potential upside of 182.41%. Given Cytek Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe EyePoint Pharmaceuticals is more favorable than Cytek Biosciences.
Summary
EyePoint Pharmaceuticals beats Cytek Biosciences on 11 of the 18 factors compared between the two stocks.
Get EyePoint Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
EyePoint Pharmaceuticals Competitors List
Related Companies and Tools
